Skip to main content

Table 4 Incidence of adverse reactions

From: Overweight with HBV infection limited the efficacy of TACE in hepatocellular carcinoma by inhibiting the upregulated HMGB1

 

Group 1a

(n = 57)

Group 2b

(n = 221)

Group 3c

(n = 58)

Group 4d

(n = 107)

P

Nausea

26

113

26

46

0.518

Vomit

4

30

5

7

0.172

Abdominal pain

27

87

26

52

0.385

Fever

9

32

20

26

0.003

Acute liver failure

1

0

0

1

0.079

Liver abscess

1

2

1

1

0.915

  1. aGroup 1: normal-weight patients without HBV
  2. bGroup 2: normal-weight patients combined HBV
  3. cGroup 3: overweight patients without HBV
  4. dGroup 4: overweight patients combined HBV
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us